Background: This case conference reviews laboratory methods for assessing oxygenation status: arterial blood gases, pulse oximetry, and CO-oximetry. Caveats of these measurements are discussed in the context of two methemoglobinemia cases. Cases: Case 1 is a woman who presented with increased shortness of breath, productive cough, chest pain, nausea, fever, and cyanosis. CO-oximetry indicated a carboxyhemoglobin (COHb) fraction of 24.9%. She was unresponsive to O 2 therapy, and no source of carbon monoxide could be noted. Case 2 is a man who presented with syncope, chest tightness, and signs of cyanosis. His arterial blood was dark brown, and COoximetry showed a methemoglobin (MetHb) fraction of 23%. Issues: Oxygen saturation (SO 2 ) can be measured by three approaches that are often used interchangeably, although the measured systems are quite different. Pulse oximetry is a noninvasive, spectrophotometric method to determine arterial oxygen saturation (S a O 2 ). CO-oximetry is a more complex and reliable method that measures the concentration of hemoglobin derivatives in the blood from which various quantities such as hemoglobin derivative fractions, total hemoglobin, and saturation are calculated. Blood gas instruments calculate the estimated O 2 saturation from empirical equations using pH and PO 2 values. In most patients, the results from these methods will be virtually identical, but in cases of increased dyshemoglobin fractions, including methemoglobinemia, it is crucial that the distinctions and limitations of these methods be understood. Conclusions: SO 2 calculated from pH and PO 2 should be interpreted with caution as the algorithms used assume normal O 2 affinity, normal 2,3-diphosphoglycerate con-
(S a O 2 ) measured by pulse oximetry was 88% and arterial blood gas results were as follows: pH ϭ 7.42 (7.35-7.45) ; P a co 2 ϭ 34 mmHg (35-45 mmHg); P a O 2 ϭ 74 mmHg (80 -105 mmHg). On 4 L of supplemental oxygen, pulse oximetry measured an oxygen saturation of 90% and arterial blood gas results were as follows: pH ϭ 7.40 (7.35-7.45) ; P a co 2 ϭ 36 mmHg (35-45 mmHg); P a O 2 ϭ 255 mmHg (80 -105 mmHg).
The patient was admitted to the medical intensive care unit, treated with 100% oxygen through a rebreather face mask, and started on antibiotics (azithromycin and ceftriaxone) with diagnoses of pneumonia and carbon monoxide poisoning after confirmation from the chemistry laboratory that the MetHb and COHb results were not mistranscribed or reversed. CO-oximetry measured at 24 and 48 h after presentation showed that the COHb decreased to 16.5% and 12.0% and FO 2 Hb increased to 81.4% and 77%, respectively, whereas MetHb remained Ͻ2% and SHb Ͻ1%. This slow decrease of COHb was inconsistent with a COHb half-life of 5-6 h with supplemental O 2 and of 1.5 h on 100% hyperbaric oxygen therapy. Additionally, multiple interviews with the patient and family members did not identify a likely source of accidental or intentional carbon monoxide poisoning. Consultations were requested from the clinical chemistry, toxicology, and hematology services to explore alternative explanations for the increased COHb. The clinical chemistry service recommended analyzing arterial blood on an alternative, continuous-wavelength CO-oximeter (Radiometer ABL 735), which gave a FO 2 Hb of 73.6%, a COHb fraction of 3.1%, and an increased MetHb fraction of 5.0%. It is important to note that all values were flagged as unreliable according to the software rules of the instrument. On the basis of the additional CO-oximetry data and the patient's improving clinical course, a provisional diagnosis of hemoglobin M (HbM) disease was made, which was subsequently confirmed as HbM Saskatoon by a methemoglobinemia evaluation performed at Mayo Laboratories and by direct amino acid sequencing of the patient's hemoglobin at Washington University.
The patient was discharged to home on day 8 with a diagnosis of community-acquired pneumonia that responded to antibiotic therapy and congenital methemoglobinemia attributable to a HbM variant.
case 2
A 52-year-old male with a past history of myocardial infarction and asthma presented to the emergency department after a syncopal episode while dancing at a nightclub. In the emergency department, he was anxious and complained of chest tightness. His current medications included aspirin, isosorbide mononitrate, albuterol, and beclomethasone inhalant. Physical examination showed that he was afebrile with a respiratory rate of 26/min, blood pressure of 75/55 mmHg, and pulse rate of 112/ min. A pallor complexion with cyanotic lips, ears, hands, and feet was noted. Lungs and heart examinations and the chest x-ray were normal. Continuous pulse oximetry indicated 87% oxygen saturation while breathing room air, increasing to 90% with 6 L of nasal oxygen. Arterial blood gas values while breathing 6 L of oxygen were as follows: pH ϭ 7.44, P a co 2 ϭ 31 mmHg; P a O 2 ϭ 123 mmHg. Arterial blood was noted to be dark brown, and CO-oximetry analysis showed a MetHb fraction of 23% (Ͻ2%), an FO 2 Hb of 74.5% (90 -95%), and COHb fraction of 0.6% (0.5-1.5%). Although he initially denied using illicit drugs, the patient confirmed that he had smoked marijuana and inhaled "amyl nitrite" before the onset of symptoms. A blood toxicology screen showed an ethanol concentration of 1520 mg/L. All other laboratory tests were normal. His chest discomfort resolved with the supplemental oxygen treatment.
Cyanosis resolved 45 min after an intravenous dose (150 mg) of methylene blue was administered over 5 min to treat the methemoglobinemia. Cardiac troponin I measurements at 0, 6, and 12 h after presentation indicated no myocardial damage. Repeat electrocardiograms remained unchanged, and CO-oximetry 12 h after admission showed a MetHb value of 0.6%. The patient was discharged on day 2 with total resolution of symptoms. At discharge, the patient described repeated inhalations of nitrite over a 30-min period before his syncopal episode and turned over a 10-mL unmarked colored bottle containing 5 mL of remaining liquid later identified as butyl nitrite by gas chromatography. The patient's NADH methemoglobin reductase activity was determined to be 15 U/g of Hb (10.1-19.4 U/g of Hb).
Discussion hemoglobin and oxygen saturation
A small amount of molecular oxygen (O 2 ) is dissolved in blood, whereas the majority (98%) is bound to hemoglobin. Hemoglobin, the O 2 transport molecule in blood, comprises four subunits: two ␣ and two non-␣ (e.g., ␤, ␥, or ␦) subunits. Each subunit contains seven helices and a porphyrin heme iron moiety. The fractional oxyhemoglobin can only be measured by a multiwavelength spectrophotometer such as a CO-oximeter. The FO 2 Hb represents the fraction of oxyhemoglobin in relation to the total hemoglobin (tHb) present (including the non-oxygen-binding hemoglobins). The fraction of any of the hemoglobin derivatives may be calculated in the same manner. In healthy individuals, the S a O 2 and FO 2 Hb are approximately equal. In the presence of substantial dyshemoglobin fractions, FO 2 Hb values will be considerably lower than the saturation determined by pulse oximetry. Although the S a O 2 typically remains within the normal limits in cases of carbon monoxide poisoning or methemoglobinemia, the O 2 capacity may be severely decreased, leading to fatal outcomes. The last approach for assessing O 2 saturation is the estimated oxygen saturation (O 2 sat), which is calculated by blood gas analyzers from pH, PO 2 , and hemoglobin values by use of empirical equations (4 ). These methods for measuring O 2 saturation parameters are discussed in more detail in the following sections.
spectrophotometric methods of analysis
Hemoglobin molecules are colored and are thus easily measured by spectrophotometric methods. The altered molecular structure of the heme moiety in different hemoglobin derivatives gives rise to unique absorbance spectra (Fig. 2) . These characteristic absorbance spectra make it possible to determine the concentration of each hemoglobin derivative present in the mixture.
Spectrophotometric methods of analysis are based on the principle that light absorbance is proportional to solute concentration. Absorbance is measured by transmitting light of a specific wavelength across a medium and measuring the intensity on the other side. Absorbance is an additive property, and it is necessary to measure absorbance at n wavelengths to obtain the concentration of n analytes. Pulse oximetry is a simple spectrophotometric method that uses only two wavelengths and measures the contribution of only two hemoglobin species, O 2 Hb and HHb. More complex photometers (CO-oximeters) are available that measure absorbance at 128 wavelengths and can report ctHb and SO 2 in addition to FHHb, FO 2 Hb, FCOHb, FHbF, FMetHb, and FSHb. it is the ratio of the absorbance at the two wavelengths during the static and pulsatile phases from which a pulse oximeter determines S a O 2 . The ratio of the red signal (660 nm) to the near-infrared (940 nm) corresponds to an oxygen saturation from a calibration curve programmed into the device. The machines are calibrated from empiric pulse oximetry data obtained from healthy individuals after induction of hypoxemia with simultaneous CO-oximetry measurement of arterial oxygen saturation (5 ). For example, an absorbance ratio (A 660 /A 940 ) of 0.43 corresponds to 100% oxygen saturation, and a ratio of 3.4 corresponds to 0% oxygen saturation on most pulse oximeters (7 ). In the absence of a dyshemoglobin, an absorbance ratio of 1.0 corresponds to an oxygen saturation of ϳ85% (7 ). The SO 2 measured by a pulse oximeter may be clinically misleading in the presence of dyshemoglobins such as COHb and MetHb. This is because the oxygen-carrying capacity of the blood will be greatly decreased when COHb or MetHb are Ͼ50% but the S a O 2 from the pulse oximeter will be close to normal. Thus, during the initial evaluation of oxygen status in an unconscious, dsypneic, or otherwise impaired patient, it is important not to rely only on pulse oximetry but to also determine the presence of high fractions of dyshemoglobins by CO-oximetry. Fig.  3 , reproduced from the study by Barker and Tremper (8 ) in dogs ventilated with carbon monoxide, shows that S a O 2 measured by pulse oximetry clearly differs from the FO 2 Hb measured by CO-oximetry with increasing COHb. O 2 Hb decreases linearly with increased COHb as carbon monoxide replaces O 2 at the heme iron. Although the S a O 2 remains Ͼ90% with increasing COHb, this value provides little information regarding the clinical picture. It is important to note that at a lethal concentration of 70% COHb, the pulse oximeter reported a saturation of 90%, although FO 2 Hb by CO-oximetry had decreased to 30%, which more accurately reflects the decreased oxygen capacity. In cases of human exposure to carbon monoxide, the difference in S a O 2 measured by pulse oximetry and FO 2 Hb by CO-oximetry has been termed the pulse oximetry gap and is typically 3-5% in healthy individuals (9 -12 ) .
Another study in dogs with intrathecal benzocaineinduced methemoglobinemia investigated the effect of increased MetHb on pulse oximetry values (13 ) . The comparison of S a O 2 measured by pulse oximetry and the FO 2 Hb from CO-oximetry in the presence of increased MetHb is shown in Fig. 4 . There is a clear difference in the S a O 2 and the FO 2 Hb as the MetHb fraction increases. As expected, the FO 2 Hb reported by CO-oximetry decreases linearly with increasing MetHb. When the MetHb concentration increases above 35%, the S a O 2 reaches a plateau of 84 -86% saturation. At this point, the pulse oximetry reading is virtually independent of the MetHb concentration. This trend toward 85% is noted in both cases presented here and in other examples of case reports of symptomatic methemoglobinemia in the literature (14 -17 ) . Zijlstra et al. (18 ) reported that although the absorbance interference attributable to COHb produces an insubstantial error in S a O 2 measured by pulse oximetry, increased MetHb gives an underestimation when S a O 2 is Ͼ70% or an overestimation at S a O 2 Ͻ70%.
This phenomenon may be explained by examining the spectroscopic signatures of the hemoglobin derivatives and understanding the principles of pulse oximetry. MetHb absorbs light almost equally at both 660 and 940 nm (Fig. 2) . Although MetHb absorbance at 660 nm is similar to that of HHb, its absorbance at 940 nm is markedly greater than that of either HHb or O 2 Hb. As a result, MetHb will contribute to the perceived absorbances of both HHb and O 2 Hb in a pulse oximeter. This increases the numerator and the denominator of the 660 nm/940 nm absorbance ratio, approximating unity. As mentioned above, a ratio of 1.0 corresponds to a saturation of 85% on many pulse oximeter calibration curves.
Barker and coworkers (8, 13 ) used animal models to demonstrate that pulse oximetry measurements in the presence of increased COHb or MetHb are not representative of the clinical picture, as seen in Figs. 3 and 4 . These studies demonstrate that although the S a O 2 typically remains within the normal limits in cases of carbon monoxide poisoning or methemoglobinemia, the O 2 capacity may be severely decreased, leading to fatal outcomes. Similar observations have been described in human case reports (6, 10, 12, 19, 20 ) . The clinically relevant value in these cases is not the S a O 2 but the FO 2 Hb and COHb or MetHb fractions, which can be measured only by a CO-oximeter. Because of spectroscopic interference, increased MetHb concentrations may have substantial effects on pulse oximetry readings, whereas COHb does not spectrophotometrically alter the S a O 2 measured by a pulse oximeter [ Fig. 3 
and Ref. (18 )].
CO-oximetry. The early CO-oximeters were simplified spectrophotometers that measured light absorbance at four or more wavelengths (21 ) . The wavelengths were chosen to correspond to the specific absorbance characteristics of the hemoglobin derivatives (Fig. 2) . By the mid-1980s, CO-oximeters could measure fractions of HHb, O 2 Hb, COHb, MetHb, and SHb by use of six wavelengths. Current models measure absorbance at 128 wavelengths and are called continuous wave spectrophotometers. The additional wavelengths improve the accuracy of the spectrum, minimize or eliminate interfering substances, and enable reporting of other derivatives (22 ) . A peak absorbance of light near 630 nm is used to characterize MetHb. On the basis of the reporting algorithm, CO-oximeters may report the various hemoglobin fractions (i.e., O 2 Hb, MetHb, COHb, and SHb) and/or the SO 2 . The assumption that FO 2 Hb is equivalent to S a O 2 does not hold in cases of increased COHb or MetHb fractions; therefore, CO-oximetry should be used to assess oxygen-carrying status via FO 2 Hb and the dyshemoglobin fractions until the presence of these dyshemoglobins is ruled out. Furthermore, it must be pointed out that neither S a O 2 nor FO 2 Hb reflects total hemoglobin-bound oxygen because this depends on Po 2 and total Hb concentration.
nonspectrophotometric methods of analysis
Blood gas analyzers are composed of a series of electrodes that provide information regarding acid/base status (pH), respiratory function (Pco 2 ), and oxygenation (Po 2 ). Highimpedance electrodes measure voltage changes to determine pH and Pco 2 , whereas Po 2 is measured as current changes at a Clark electrode (4 ). Po 2 refers to dissolved gas in blood. The concentration of dissolved oxygen (cdO 2 ) is linearly related to the partial pressure of oxygen in blood, according to Henry's law, where ␣O 2 , the solubility constant of O 2 , is 0
:
The relationship between the calculated SO 2 , often referred to as O 2 sat, and Po 2 may not always be linear. SO 2 is calculated from the pH and Po 2 values and the standard ODC for oxygen saturation (2, 4 ) . Unfortunately, this approach to calculating SO 2 assumes a normal ODC. In hospitalized patients, the assumption that the ODC is normal is frequently erroneous because it relies on normal pH, temperature, DPG concentrations, and no inherited or acquired dyshemoglobins.
Salyer et al. (23 ) tested this method in 30 patients admitted to a pediatric intensive care unit. Arterial blood was analyzed by a blood gas instrument and a COoximeter. Comparing SO 2 as measured by CO-oximetry and as calculated from a blood gas instrument yielded a high correlation and a smaller difference for SO 2 Ն95% and a poor correlation for SO 2 Ͻ95% (Fig. 5) . This work confirms that calculated SO 2 is not an accurate measurement of O 2 status in hospitalized patients, especially at SO 2 Ͻ95%. Although the mean SO 2 was not different between the two methods, the individual values varied as much as 6% of the measured SO 2 . This last point is striking because the authors state that a 2% difference would be clinically important.
methemoglobinemia
Methemoglobinemia refers to the oxidation of ferrous iron [Fe(II)] to ferric iron [Fe(III)] within the hemoglobin complex (24, 25 ) . Once MetHb is formed, the hemoglobin loses its ability to transport oxygen, leading to tissue hypoxia and, in severe cases, death. Methemoglobinemia is most commonly the result of exposure to an oxidizing chemical, but it may also arise from genetic or idiopathic etiologies (Table 2 ). Methemoglobinemia may be misinterpreted as carbon monoxide poisoning because the presenting symptoms are similar. CO-oximetry values, blood color, and response to supplemental O 2 therapy aid in the differential diagnosis. Additionally, carbon monoxide poisoning does not produce cyanosis. MetHb Ͼ15% produces asymptomatic cyanosis that is unresponsive to supplemental O 2 . MetHb fractions Ͼ20% are associated with the following symptoms: dyspnea, fatigue, nausea, dizziness, headache, and syncope (Table 3 ) (24, 25 ) . Symptoms worsen as the MetHb increases, with a high occurrence of mortality observed at MetHb values Ͼ70%.
A certain amount of physiologic MetHb formation occurs continuously as a result of endogenous oxidation. Several mechanisms exist in the erythrocytes to reduce Clinical Chemistry 51, No. 2, 2005 MetHb to HHb; therefore, in healthy individuals, MetHb comprises only ϳ1% of total hemoglobin. The primary mode of MetHb reduction, accounting for 99% of daily MetHb reduction, is the cytochrome b 5 -methemoglobin reductase (NADH methemoglobin reductase) system (26 ) . Cytochrome b 5 -methemoglobin reductase is a twoenzyme system comprising cytochrome b 5 and cytochrome b 5 reductase. A schematic of the enzymatic pathways for the reduction of MetHb to HHb is shown in Fig.  6 (25 ) . Other mechanisms of MetHb reduction (ascorbic acid or glutathione reduction and NADPH dehydrogenase) are considered minor pathways under physiologic conditions (27, 28 ) , but these minor pathways are capable of reducing large amounts of MetHb when the primary reduction mechanism is compromised. For example, patients with congenital cytochrome b 5 -methemoglobin reductase deficiencies are able to maintain MetHb Ͻ50% (24, 25 ) .
The majority of methemoglobinemia cases are acquired and mild, and therapy is focused on removal of the inciting toxin, oxygen administration, and observation. The half-life of MetHb is ϳ1 h (t 1/2 ϭ 55 min) if reductase mechanisms are normal (29, 30 ) . Severe methemoglobinemia is treated by the administration of a potent electron donor such as methylene blue (31) (32) (33) . Therapy should be initiated at MetHb Ͼ20% in symptomatic and Ͼ30% in asymptomatic patients. The current recommended dosage of methylene blue is 1-2 mg/kg of body weight administered intravenously over a 5-min period (31, 33, 34 ) . Generally, the MetHb concentration decreases significantly within 1-2 h after a single dose; additional doses may be necessary but should not exceed a total of 7 mg/kg. Doses of methylene blue Ͼ15 mg/kg can paradoxically incite methemoglobinemia.
During methylene blue therapy, an alternative enzyme system, NADPH dehydrogenase, becomes the primary mechanism for MetHb reduction (31 ) . NADPH dehydrogenase reduces MetHb only in the presence of an exogenous catalyzing agent such as methylene blue and is not responsible for endogenous MetHb reduction (Fig. 6) . Methylene blue itself is a powerful oxidant, and it is actually the metabolic product, leukomethylene blue, that acts as the reducing agent. Failure of methylene blue to resolve methemoglobinemia may be a result of NADPH dehydrogenase deficiency, glucose-6-phosphate dehydrogenase deficiency (no NADPH), or a hemoglobin variant such as HbM (see below) (24 ) . Less severe cases of congenital methemoglobinemia may be managed with an antioxidant such as ascorbic acid. Ascorbic acid is not indicated in the treatment of acquired methemoglobinemia because the rate at which it reduces methemoglobin is lower than that of the intrinsic enzymatic pathways (24, 35 ) .
acquired methemoglobinemia
Toxin-induced methemoglobinemia occurs from exposure to oxidizing agents and represents the most common cause of methemoglobinemia. Case reports indicate that local topical anesthetics, dapsone, and recreationally abused nitrite drugs are the predominant causative agents (16, 20, 30, 32, 34, 36 -52 ) . Exposure to these agents can occur by ingestion, inhalation, and absorption across skin and mucous membranes. Some of the common causative agents are listed in Table 2 and include aniline, benzocaine, dapsone, phenazopyridine (pyridium), nitrites, nitrates, and naphthalene (34 ) .
Toxins can oxidize hemoglobin to MetHb through several mechanisms: direct oxidation of hemoglobin, indirect oxidative pathways, and via metabolic activation (34 ) . Direct oxidizers, such as benzocaine, prilocaine, and nitroaromatics, react directly with hemoglobin to form MetHb. The nitrites are powerful reducing agents that indirectly oxidize hemoglobin by reducing oxygen to the free radical superoxide or water to hydrogen peroxide. These highly reactive species oxidize hemoglobin to MetHb. Alternatively, drug metabolites and not the parent drug can be the causative agents. Aniline is metabolized to a free radical, phenylhydroxylamine, which, like nitrite, reacts with O 2 to form oxygen free radicals and then MetHb. Both dapsone and its hydroxylamine metabolite are capable of oxidizing hemoglobin. Variability in metabolism, rate of absorption, or enterohepatic recirculation among individuals may influence the severity and duration of toxin-induced methemoglobinemia.
Infants are particularly susceptible to toxin-induced methemoglobinemia because of lowered erythrocyte cytochrome b 5 -methemoglobin reductase activity (50 -60% of adult activity) until 4 months of age (53, 54 ) . Case reports of infant-acquired methemoglobinemia include well-water nitrate contamination and topical teething gels containing benzocaine as the oxidizing agents (55) (56) (57) .
congenital methemoglobinemias
Enzyme deficiencies. Hereditary deficiencies of the erythrocyte reductive enzymatic pathways, most commonly cytochrome b 5 reductase, lead to inherited methemoglobinemia (58 -61 ) . These rare deficiencies are inherited in an autosomal recessive pattern, and patients may be deficient in either cytochrome b 5 or cytochrome b 5 reductase (26, 62 ) . Homozygous individuals are identified at, or very shortly after, birth with unexplained cyanosis. These individuals have moderately increased MetHb concentra- tions (10 -20%), which are usually well tolerated, and mild skin discoloration (slate or chocolate gray) (26, 62 ) .
HbM variants. HbM denotes a group of abnormal hemoglobins with mutations in the globin chain that stabilize the heme iron in the oxidized form. A histidine-totyrosine substitution in either the ␣-or ␤-chain is identified in most HbM molecules (26, 62 ) . This aberration leads to the formation of an iron-phenolate complex that resists reduction. Several mutations have been characterized and are listed in Table 4 . Depending on the mutation, the O 2 affinity may be increased or decreased. This disorder is inherited in an autosomal dominant pattern, and the homozygous form is presumed to be incompatible with life. It is important to note that the structural change in the heme iron translates into an absorbance spectrum that is significantly different from that of typical MetHb ( Fig. 7) 
Summary case 1
The clinical chemistry and hematology consults noted the existence of mild polycythemia and, suspecting a high O 2 affinity HbM variant, recommended a methemoglobinemia evaluation. This was suspected because it has previously been documented that HbM will yield abnormally increased COHb and SHb but normal MetHb values when CO-oximetry is performed with a discrete sixwavelength CO-oximeter such as the Radiometer 625 ABL (1 ). As a result, a congenital methemoglobinemia attributable to HbM may be mistakenly diagnosed as carbon monoxide poisoning or toxic sulfhemoglobinemia, as happened with this patient (despite her acknowledgement of a family history of chronic methemoglobinemia at presentation). The results confirming the HbM diagnosis were returned after the patient had been discharged.
case 2
The NADPH dehydrogenase in this individual was clearly functional as evidenced by his response to methylene blue. The possibility of a cytochrome b 5 -methemoglobin reductase deficiency was considered because of prolonged cyanosis and because butyl nitrite had not been shown to cause such a symptomatic methemoglobinemia.
In this patient, syncope was likely a result of hypoxia attributable to MetHb and the hypotensive effects of the butyl nitrite. The MetHb value was obtained ϳ60 min after the patient's syncopal episode. With a half-life of 55 min, it is likely that the peak MetHb value before his arrival in the emergency department was considerably higher than 23%. Furthermore, the patient's history of isosorbide mononitrate use likely increased his susceptibility to both the vasodilatory effects and oxidizing potential of butyl nitrite.
